LEADER 00955nam0-22003371i-450-
001 990002409080403321
005 20021010
010   $a0-8016-2704-4
035   $a000240908
035   $aFED01000240908
035   $a(Aleph)000240908FED01
035   $a000240908
100   $a20021010d--------km-y0itay50------ba
101 0 $aita
200 1 $aClinical chemistry$etheory, analysis and correlation$fLawrence A. Kaplan, Amadeo J. Pesce.
205   $a2. ed.
210   $aSt. Louis [etc.]$cMosby Company$d1989.
215   $aXXVIII, 1146 p., 63 p. di indice$cill.$d29 cm
610 0 $aAnalisi mediche.
610 0 $aBiochimica
676   $a612.015
700  1$aKaplan,$bLawrence A.$0101433
702  1$aPesce,$bAmadeo J.
801  0$aIT$bUNINA$gRICA$2UNIMARC
901   $aBK
912   $a990002409080403321
952   $a90 Q 2A 03$b699$fFMEBC
959   $aFMEBC
996   $aClinical chemistry$9440380
997   $aUNINA
DB    $aING01

LEADER 00766nam0-2200253 --450 
001 9910757500803321
005 20231123100900.0
010   $a9781108494526
100   $a20231123d2020----kmuy0itay5050    ba
101 0 $aeng
102   $aGB
105   $a        001yy
200 1 $aAdmissibility of shareholder claims under investment treaties$fGabriel Bottini
210   $aCambridge$cCambridge University Press$d2020
215   $aIX, 335 p.$d24 cm
676   $a346.092$v23$zita
700  1$aBottini,$bGabriel$01436044
801  0$aIT$bUNINA$gREICAT$2UNIMARC
901   $aBK
912   $a9910757500803321
952   $aX K 161$b2021/540$fFGBC
959   $aFGBC
996   $aAdmissibility of shareholder claims under investment treaties$93594140
997   $aUNINA